Central antinociception induced by μ-opioid receptor agonist morphine, but not δ- Or κ-, is mediated by cannabinoid CB 1 receptor

British Journal of Pharmacology

Volumn 158, Issue 1, 2009, Pages 225-231

  Da Fonseca Pacheco, Daniela ^a   Klein, André ^a   Perez, Andréa Castro ^a   Da Fonseca Pacheco, Cinthia Mara ^a   De Francischi, Janetti Nogueira ^a   Lopes Reis, Gláucia Maria ^a   Duarte, Igor Dimitri Gama ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bremazocine; CB 1 receptor; CB 2 receptor; Central antinociception; Morphine; SNC80

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; BREMAZOCINE; CANNABINOID 1 RECEPTOR; DELTA OPIATE RECEPTOR; ENDOCANNABINOID; KAPPA OPIATE RECEPTOR; METHYLARACHIDONYLFLUOROPHOSPHONATE; MORPHINE; MU OPIATE RECEPTOR; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWISS WEBSTER MOUSE; TAIL FLICK TEST; THERMAL STIMULATION;

ANALGESICS, OPIOID; ANIMALS; INDOLES; MALE; MICE; MORPHINE; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 69249232082     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00310.x     Document Type: Article

References (57)

1. Bidaut-Russell M, Devane WA, Howlett AC (1990). Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem 55 : 21 26.
2. 2 receptor-dependent mechanism. Mol Pharmacol 65 : 999 1007.
3. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW et al. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 : 43 50.
4. Childers SR (1991). Opioid receptor-coupled second messengers. Life Sci 48 : 1991 2003.
5. 9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 289 : 859 867.
6. Cossu G, Ledent C, Parmentier M, Maldonado R, Valverde O (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Brain Res 118 : 61 65.
7. 9-tetrahydrocannabinol in the arthritic rat. Eur J Pharmacol 493 : 65 74.
8. Cravatt BF, Lichtman AH (2002). The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 121 : 135 148.
9. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DQ, Martin DR et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98 : 9371 9376.
10. D'Amour FE, Smith DL (1941). A method for determining loss of pain sensation. J Pharmacol Exp Ther 72 : 74 79.
11. Degroot A, Nomikos GG (2007). In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Curr Opin Pharmacol 7 : 62 68.
12. Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z et al. (1997). Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol 53 : 255 260.
13. Dinh TP, Freund TF, Piomelli D (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121 : 149 158. (Pubitemid 36044549)
14. Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA et al. (2004). Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19 : 678 686.
15. Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83 : 1017 1066.
16. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232 : 54 61.
17. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997). Binding of the non-classical cannabinoid CP 55940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61 : 191 197.
18. 2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 : 10 23. (Pubitemid 43255471)
19. Hájos N, Freund TF (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43 : 503 510.
20. Haley TJ, McCormick WG (1957). Pharmacological effects produced by intracerebroventricular injection of drugs in the conscious mouse. Br J Pharmac Chemother 12 : 12 15.
21. Haller VL, Stevens DL, Welch SP (2008). Modulation of opioids via protection of anandamida degradation by fatty acid amide hydrolase. Eur J Pharmacol 600 : 50 58.
22. Ho WSV, Randall MD (2007). Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150 : 641 651.
23. Hohmann AG (2002). Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121 : 173 190.
24. Hohmann AG, Suplita RL (2006). Endocannabinoid mechanisms of pain modulation. AAPS J 8 : 693 708.
25. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 : 161 202.
26. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102 : 3093 3098.
27. Jhaveri MD, Richardson D, Kendall DA, Barret DA, Chapman V (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26 : 13318 13327.
28. Kauser S, Schallreuter KU, Thody AJ, Gummer C, Tobin DJ (2003). Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol 120 : 1073 1080.
29. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D et al. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42 : 769 776.
30. La Rana G, Russo R, Campolongo P, Bortolato M, Mangieri RA, Cuomo V et al. (2006). Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14- tetraenamide J Pharmacol Exp Ther 317 : 1365 1371.
31. 2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci 17 : 91 95.
32. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M et al. (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316 : 969 982.
33. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 : 239 245.
34. Manzaneres J, Corchero J, Romero JJ, Fernandez-Ruiz JA, Ramos JÁ, Fuentes JA (1999). Pharmacological and biochemical interactions between opioids and cannabionoids. Trends Pharmacol Sci 20 : 287 294.
35. 1 knockout mice. Eur J Neurosci 12 : 4038 4046.
36. Massi P, Vaccani A, Romorini S, Parolaro D (2001). Comparative characterization in the rat of the interaction between cannabinoids and opioids for their immunosopressive and analgesic effects. J Neuroimmunol 117 : 116 124.
37. 2 receptors in brain. Ann N Y Acad Sci 1074 : 514 536.
38. B receptors: from pharmacology to molecular biology. Acta Pharmacol Sin 21 : 111 123.
39. Pacheco DF, Klein A, Perez AC, Pacheco CMF, Francischi JN, Duarte ID (2008). The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol 154 : 1143 1149.
40. Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano C et al. (2006). Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 24 : 2011 2020.
41. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63 : 569 611.
42. Pertwee RG (2004). Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2 : 9 29.
43. Pugh G, Smith PB, Dombrowski DS, Welch SP (1996). The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 279 : 608 616.
44. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ and κ opioid receptors. Eur J Pharmacol 318 : 11 16. (Pubitemid 27033197)
45. 1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148 : 387 395.
46. 2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126 : 665 672.
47. 2 cannabinoid receptors in mast cells. J Immunol 170 : 4953 4962.
48. 2 receptors. Science 310 : 329 332.
49. Singh VK, Bajpai K, Biswas S, Haq W, Khan MY, Mathur KB (1997). Molecular biology of opioid receptors: recent advances. Neuroimmunomodulation 4 : 285 297.
50. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L et al. (1996). The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebral granule neurons. Proc Natl Acad Sci USA 93 : 3984 3989.
51. Smith FL, Cichewiez D, Martin ZL, Welch SP (1998). The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 60 : 559 566.
52. Varvel SA, Cishewicz DL, Lichtman AH (2004). Interactions between cannabinoids and opioids. In : Wenger Tibor (eds). Recent Advances in Pharmacology and Physiology of Cannabinoids. Kerala Press : Cochin, pp. 157 182.
53. Welch SP (1993). Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174864 or naloxone in mice. J Pharmacol Exp Ther 265 : 633 640.
54. Welch SP, Eads M (1999). Synergistic interactions of endogenous opioids and cannabinoids systems. Brain Res 848 : 183 190.
55. Williams J, Haller VL, Stevens DL, Welch SP (2008). Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 584 : 78 86.
56. Wilson AR, Maher L, Morgan MM (2008). Repeat cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 55 : 1219 1225.
57. 1 receptors in mood and anxiety disorders. Behav Pharmacol 16 : 315 331.